Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3
Status:
Recruiting
Trial end date:
2023-01-21
Target enrollment:
Participant gender:
Summary
An open-label, single center study with 99mTc-ADAPT6 and 99mTc-DARPinG3 SPECT and biopsies of
primary tumour in HER2-positive Breast Cancer before system (chemo/targeted) therapy, where
the primary endpoint of the study is to compare imaging properties of 99mTc-ADAPT6 and
99mTc-DARPin G3 SPECT in HER2-positive breast cancer patients.
Phase:
N/A
Details
Lead Sponsor:
Tomsk National Research Medical Center of the Russian Academy of Sciences